Anabolic Steroids/Hormones
Halotestin
Also called Fluoxymesterone · Halo
Halotestin, or Halo, comes up around powerlifting strength, intense training drive and a harder-looking contest physique rather than large weight gain. Some users like the focus; others describe anger and an experience they would not repeat. Serious liver and other health risks remain even when a workout feels better.
Dosage & duration
Published reports · oral fluoxymesterone
Mullen online-use compilation
Reported use · unapproved regimen- Dose
- 10–40 mg total per day
- How often
- Daily total; split not specified
- How long
- Not specified in the compilation
Reported internet/supplier figures, not a tested safe course. A separate reported example lasts 4–6 weeks; it is not combined into this regimen.
Halo at a glance
Training drive can reach beyond the gym
What users seek
-
Strength and focus
People seek intense training drive and a harder contest look without much scale-weight gain.
What users report
-
Anger outside training
Some describe unwanted irritability despite liking their workouts; other drugs can be involved.
Serious liver concerns The label warns about serious liver injury; a short course does not establish safety.
What do users want from Halo?
Powerlifters discuss it for strength without a large scale-weight increase; physique users discuss a harder appearance near competition. Many questions are really about whether the intense “drive” people describe translates into a better session. The accounts are uncontrolled and cannot predict a performance gain.
Does the aggression stay in the gym?
Not necessarily. Some people report unwanted anger outside the gym despite positive workouts. Other drugs may be involved, so an account cannot isolate Halo’s role. A powerful-feeling workout is an incomplete way to judge the experience.
What do the dose reports mean?
The visible daily range comes from a compilation of online reports, not a prescribing trial. The older medical label uses different indication-specific amounts, including 5–20 mg/day for male replacement. Neither context establishes a safe competitive-use cycle.
What should stand out before the plot?
The label warns about cholestatic liver injury, serious liver abnormalities, cholesterol changes and fluid retention. Reproductive suppression and androgenic effects also matter. Yellow eyes, dark urine or severe itching need medical assessment; waiting for the curve to fall is not a response to suspected liver injury.
Timing is not an outcome forecast
The retained plot compares modeled timing. It cannot predict strength, mood, drug-test results or whether a product contains fluoxymesterone.
Model details: Halotestin · relative timing
Compare timing and buildup for this compound. The values are not blood concentrations or a measure of strength.
Shows a relative timing scenario; absolute blood concentrations are not calibrated.
Timing assumptions and sources
Primary crossover half-life 2 h; midpoint of reported 1–2 h peak times, no oral-specific point.
One 1 mg input peaks at 1 relative unit after a single dose. Other amounts scale proportionally; overlapping doses add when accumulation is on. Different compounds use separate relative scales.
- Timing half-life used
- 2 hours
- Absorption half-life assumed
- 0.6075545 hours
- Reference amount for the relative scale
- 1 mg
- The faster rate is inferred to match the 1.5 h source-scoped peak time; absorption half-life 0.6075545274580504 h is a mathematical shape parameter, not separately measured.
- A single 1-unit input has a peak of 1 relative unit; scaling and repeated-dose addition are mathematical assumptions. This normalization is independent of the example dose.
- Cannot select a point from pooled 40–150 ng/mL as the oral mean.
- StoredF 0.57 is not established by this relative-bioavailability experiment.
- MidpointTmax 1.5 h is an estimate within the reported 1–2 h range.
- Capponi 1985 fluoxymesterone serum assay/PK
6 subjects, 10 mg oral/buccal; Tmax 1–2 h, harmonic mean half 2 h. Oral/buccal Cmax ratio 0.80 and AUC ratio 0.76; not absoluteF.
halotestin-relative-timing-2026-10 · version 1
Safety and interaction notes Read the limitations and discuss clinical questions with a professional
- Aromatizes
- No
- DHT derivative
- No
Common questions
Is Halotestin mostly for size?
Users more often discuss strength and conditioning. That preference is not a controlled comparison with bulking drugs.
Does a brief cycle avoid liver risk?
No safe nonmedical duration is established by the sources used here.
Is Halo just a stronger pre-workout?
No. It is an androgen drug, not a workout supplement. Reports of rapid focus or aggression do not establish a dependable strength effect, and a pre-workout label does not remove its liver or other risks.
Sources Labels, studies and notes behind this guide
Catalog evidence: Other human research. This describes the type of evidence, not a clinical review of every claim.
Summary and fact source checks: 2026-10-10, 2026-10-07. This records source checking, not medical review of the whole page.
Notes on the quick facts
- Why people seek it
- User reports emphasize effort and appearance more than steady size gains.
- Outside the gym
- Some accounts turn from a strong workout to irritability that disrupts ordinary life.
- Main trade-off
- A short course does not make this oral steroid liver-safe.
- 1. DailyMed — Halotestin label
Archived label: male replacement 5–20 mg daily, once or divided; liver, lipid, edema and androgen warnings. Not evidence of current availability.
- 2. Mullen et al. — online steroid-use compilation
Search table lists fluoxymesterone 10–40 mg/day in reported nonmedical use; duration and split absent. Not clinical recommendation.
- 3. Capponi 1985 fluoxymesterone serum assay/PK
6 subjects, 10 mg oral/buccal; Tmax 1–2 h, harmonic mean half 2 h. Oral/buccal Cmax ratio 0.80 and AUC ratio 0.76; not absoluteF.
- 4. Capponi et al. 1985 — oral and buccal fluoxymesterone
Abstract checked: six subjects, 10 mg oral versus buccal tablet; peak 1–2 hours, harmonic mean half-life 2 hours. Oral/buccal exposure ratio is not absolute bioavailability.
- 5. ChEBI — fluoxymesterone chemical identity (CHEBI:5120)
Authoritative structure/names checked: 9α-fluoro-11β-hydroxy-17-methyltestosterone with an androst-4-en-3-one skeleton. It is testosterone-derived, not a 5α-reduced DHT derivative; consistent with the Halotestin label chemical name.
- 6. DeFazio et al. 1984 — fluoxymesterone and hot flushes
Primary human case report abstract checked through Europe PMC. Explicitly identifies fluoxymesterone as non-aromatizable and reports no significant change in non-SHBG-bound estradiol in this one case. Supports classification, not a universal clinical effect.
Related compounds and examples
Related compounds
Anadrol
Anadrol is sought for rapid size, fullness and strength, and is often compared with Dianabol. The practical catch is that some users report feeling tired or losing their appetite while trying to gain weight. A fast scale increase is not all new muscle, and the liver, cholesterol and fluid-retention risks still matter.
Dianabol
Dianabol attracts lifters who want fast strength gains and a fuller, bigger look. Users also describe a feel-good effect, but bloating and painful back pumps can spoil the appeal. Rapid scale gain is not all lasting muscle; blood-pressure and liver risks matter even when training feels great.
Turinabol
Turinabol attracts lifters who want better gym stamina, strength and a fuller look without the big water-weight swing they associate with Dianabol. Reports are mixed: some feel more athletic, while others find headaches, shin pumps or stomach trouble outweigh the benefit. Its mild reputation is not a safety guarantee.